The LDN Book, Volume Two

Know about the book -

The LDN Book, Volume Two is written by Linda Elsegood and published by Chelsea Green Publishing. It's available with International Standard Book Number or ISBN identification 1603589910 (ISBN 10) and 9781603589918 (ISBN 13).

A comprehensive examination of Low Dose Naltrexone—a little-known drug with big potential “[LDN] raises hopes of reversing memory loss in old age.”—the Guardian A drug that is simultaneously affordable, devoid of severe side effects, and applicable to a wide range of diseases is not often found in the modern pharmaceutical landscape. But as medical professionals and researchers alike continue to discover, Low Dose Naltrexone (LDN) boasts this remarkable combination. LDN, originally prescribed in higher doses as a treatment for opioid addiction, works by blocking opioid receptors, thereby stimulating the production of endorphins, mitigating the inflammatory process, and stabilizing the immune response. Prescribed off-label and administered in small daily doses, this generic drug has proven useful in treating many different ailments. Expanding on the information presented in The LDN Book, Volume 1, which showcased LDN’s efficacy in treating conditions such as lupus, thyroiditis, autism spectrum disorder, and chronic fatigue, Volume 2 highlights the latest clinical trials, case studies, and research with explanations from a dozen medical professionals on how they are using LDN to help patients suffering from: Chronic pain Parkinson’s disease Dermatologic conditions Traumatic brain injury Lyme disease and more The LDN Book, Volume 2 is both a resource for practitioners, pharmacists, and patients, and a renewed call for further research on the healing potential of this generic drug.